Cargando…
Enhancing effect of β-elemene emulsion on chemotherapy with harringtonine, aclacinomycin, and Ara-c in treatment of refractory/relapsed acute myeloid leukemia
Objective : This study is to determine the curative effect of β-elemene emulsion on chemotherapy in the treatment of refractory/relapsed acute myeloid leukemia (AML). Methods : In the β-elemene emulsion plus HAA chemotherapy (harringtonine, aclacinomycin, Ara-c group) group, 120 cases received β-ele...
Autores principales: | Zheng, Cuiping, Cai, Xiaoping, Wu, Shenghao, Liu, Zhen, Shi, Yuejian, Zhou, Wenjin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Professional Medical Publicaitons
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320713/ https://www.ncbi.nlm.nih.gov/pubmed/25674121 http://dx.doi.org/10.12669/pjms.306.5207 |
Ejemplares similares
-
Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations
por: Li, Limin, et al.
Publicado: (2018) -
Rethinking Biosynthesis of Aclacinomycin A
por: Xu, Ziling, et al.
Publicado: (2023) -
Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
por: Popescu, Bogdan, et al.
Publicado: (2019) -
Harringtonine: A more effective antagonist for Omicron variant
por: Hu, Shiling, et al.
Publicado: (2023) -
Aclacinomycin A Sensitizes K562 Chronic Myeloid Leukemia Cells to Imatinib through p38MAPK-Mediated Erythroid Differentiation
por: Lee, Yueh-Lun, et al.
Publicado: (2013)